On the US charts today, Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) is rising sharply. As of the last check in the current session, it was up 56.66% to $1.88. Following announcement of a substantial development in the company’s blood data gathering and analysis technology, Inspira’s stock price surged.
Today, Inspira (IINN) reported a major development made by its team of professionals in the field of sensor technology. This innovation provides continuous and real-time blood monitoring capabilities compared to conventional blood gas analyzer systems used in hospitals, which usually need sporadic blood draws. It achieves 95% accuracy compared to ordinary blood gas analyzers. This development suggests that IINN may join the disposables industry.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The formulation of the inaugural HYLA variation, which is essential to this progress, is a major step toward regulatory submission. This will pave the way for Inspira to file a 510(k) with the United States Food and Drug Administration (“FDA”) in the second half of 2024. This sensor technology was submitted to the FDA in September 2023, with a goal of approval in the first half of 2024. It is intended to be combined with the company’s INSPIRA ART100.
With its continuous, real-time blood information collecting and processing capabilities, the HYLA Blood Sensor line is poised to revolutionize intensive care unit (ICU) operations. With the goal of enhancing medical processes and device efficiency, this improves patient care by providing crucial insights and alarms.
Inspira uses hospital partnerships and internal lab testing to conduct clinical research as well as development for the HYLA Blood Sensor range. This strategy has made it possible to specify the Blood Sensor’s disposable components and operations in conjunction with HYLA’s intended razor blade business model. Plans exist to provide a Blood Sensor variation as a stand-alone device, despite its primary design being for INSPIRA ART devices.
